Drugs / ESG206
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05263739 | Dec 2025 → Aug 2026 | B-cell neoplasm | Shanghai Escugen Biotechnology Co., Ltd | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT05822843 | Aug 2023 → Jan 2025 | B-cell neoplasm | Shanghai Escugen Biotechnology Co., Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06853444 | May 2025 → Mar 2026 overdue | autoimmune thrombocytopenia | Shanghai Escugen Biotechnology Co., Ltd | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07375524 Comparator | Mar 2026 → Dec 2027 expected | Sjogren syndrome | Shanghai Escugen Biotechnology Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ESG206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05263739 ↗ |
| Modality | Monoclonal antibody | “Anti-BAFFR mAb, ESG206” NCT05263739 ↗ |
| Route | Intravenous | “Administered via intravenous (IV) infusion” NCT05263739 ↗ |